G6PC1 and Hypoglycemia: In the current study with G6pc–/– mice, the combination of high-dose genome-editing vectors with bezafibrate resulted in the most efficacious outcome, as determined by the primary endpoint for clinical trials in GSD Ia (25), the prevention of hypoglycemia, which correlated with transgene integration.